Unnatural helical peptidic foldamers as protein segment mimics

P Sang, J Cai - Chemical Society Reviews, 2023 - pubs.rsc.org
Unnatural helical peptidic foldamers have attracted considerable attention owing to their
unique folding behaviours, diverse artificial protein binding mechanisms, and promising …

Glucagon, from past to present: a century of intensive research and controversies

AJ Scheen, PJ Lefèbvre - The Lancet Diabetes & Endocrinology, 2023 - thelancet.com
Summary 2022 corresponds to the 100th anniversary of the discovery of glucagon. This
TimeCapsule aims to recall the main steps leading to the discovery, characterisation, and …

Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906

A Jungnik, J Arrubla Martinez… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To report two phase I studies of the novel subcutaneous glucagon‐like peptide‐1
receptor/glucagon receptor (GLP‐1R/GCGR) dual agonist BI 456906 versus placebo in …

Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial

CW le Roux, O Steen, KJ Lucas, E Startseva… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Obesity is a widespread and chronic condition that requires long-term
management; research into additional targets to improve treatment outcomes remains a …

Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice

T Wu, Y Zhang, W Li, Y Zhao, H Long… - Journal of Agricultural …, 2021 - ACS Publications
In this study, we aimed to explore the antidiabetic effects of Lactobacillus rhamnosus LRa05
on glucose metabolism and gut microbiota in type 2 diabetes mellitus (T2DM) mice. Our data …

The incretin/glucagon system as a target for pharmacotherapy of obesity

S Del Prato, B Gallwitz, JJ Holst, JJ Meier - Obesity Reviews, 2022 - Wiley Online Library
Obesity is a chronic, multifactorial, relapsing disease. Despite multicomponent lifestyle
interventions, including pharmacotherapy, maintaining bodyweight loss is challenging for …

Transcriptional regulation of adipocyte lipolysis by IRF2BP2

Y Chen, L Liu, R Calhoun, L Cheng, D Merrick… - Science …, 2025 - science.org
Adipocyte lipolysis controls systemic energy levels and metabolic homeostasis. Lipolysis is
regulated by posttranslational modifications of key lipolytic enzymes. However, less is …

Role of estrogen and its receptors in adipose tissue glucose metabolism in pre-and postmenopausal women

F Ahmed, PG Kamble, S Hetty, G Fanni… - The Journal of …, 2022 - academic.oup.com
Context Reduced estrogen levels in postmenopausal women predispose them to metabolic
side effects, including insulin resistance and type 2 diabetes; however, the cellular …

The impact of incretin‐based medications on lipid metabolism

H Yaribeygi, M Maleki, AE Butler… - Journal of Diabetes …, 2021 - Wiley Online Library
Pathophysiological pathways that are induced by chronic hyperglycemia negatively impact
lipid metabolism. Thus, diabetes is commonly accompanied by varying degrees of …

Glucagon, cyclic AMP, and hepatic glucose mobilization: A half‐century of uncertainty

RL Rodgers - Physiological Reports, 2022 - Wiley Online Library
For at least 50 years, the prevailing view has been that the adenylate cyclase (AC)/cyclic
AMP (cAMP)/protein kinase A pathway is the predominant signal mediating the hepatic …